Drug
Mrtx849
Mrtx849: highest development phase Phase 3, developed by Mirati Therapeutics, Zai Lab. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Mirati Therapeutics, Zai Lab
Trials
| Drug | Phase | Indication |
|---|---|---|
| MRTX849 NCT04793958 | Phase 3 | Advanced Colorectal Cancer |
| MRTX849 NCT04685135 | Phase 3 | Metastatic Non Small Cell Lung Cancer |
| MRTX849 NCT03785249 | Phase 1/2 | Advanced Cancer |
| MRTX849 NCT05263986 | Phase 1 | Advanced or Metastatic Solid Tumor |
| MRTX849 NCT05722327 | Phase 1 | Colon Cancer |
| MRTX849 NCT04975256 | Phase 1 | Advanced Cancer |
| MRTX849 NCT04330664 | Phase 1 | Advanced Cancer |
| MRTX849 NCT05178888 | Phase 1 | Advanced Solid Tumor |
Latest
No recent events.
Follow Mrtx849 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.